Skip to content
CancerIndex

Publication

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.

Authors not recorded

Nat Med2015PMID 25686104PMC4352133stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
25686104
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
ARID1A Loss1
GSK126Ovarian Clear Cell CarcinomaUNRESOLVEDPredictiveDSupports Sensitivity Response4accepted
EID2983

A screen was performed to identify small molecule inhibitors that inhibit growth of ARID1A inactivated cells using shRNA knockdown in ARID1A wild-type ovarian clear cell carcinoma (OCCC) cell line RMG… (full text at CIViC)

PMID 25686104 · Bitler et al., 2015 · Open in CIViC

civic